Competing interests
Pierre, J.B.
ONCOLOGY
F.G. received fees for oral communication from Eli Lilly, Sanofi, Bristol Myers Squibb, AstraZeneca and Amgen, received funding for clinical trials from AstraZeneca, received travel grants from Roche France, Amgen and Servier and is an advisory board member for Merck Serano, Amgen, Roche France and Sanofi, all outside of the submitted work. B.C. received honoraria from Amgen, Bayer, Beigine, Biocartis, Bristol Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Merck, Pfizer, Pierre Fabre, Roche, Sanofi, SeqOne, Servier and Takeda. J.B. has received personal fees from Roche, Boehringer Ingelheim, Bristol Myers Squibb, Merck Sharp & Dohme, Bayer and Servier (served on the advisory board and participated in educational sessions for all) and personal fees from AstraZeneca (served on the advisory board, participated in educational sessions and collaborated on grants), all outside of the submitted work. C.B. has received research grants from Bayer and Roche and was an advisory board member of Bayer, Merck Sharp & Dohme and Pierre Fabre. None of these companies had a role in the study design, analysis or interpretation of the results. R.C. reports personal fees and non-financial support from Bristol Myers Squibb and MSD Oncology during the conduct of the study as well as personal fees from Amgen and Pierre Fabre, non-financial support from Mylan Medical and grants from the Servier Institute, all outside of the submitted work. J.T. has received honoraria as a speaker and/or in an advisory role from Merck KGaA, Sanofi, Roche Genentech, Merck Sharp & Dohme, Bristol Myers Squibb, AstraZeneca, Servier, Pierre Fabre, Sandoz and Amgen, all outside of the submitted work. All other authors declare no competing interests.